RANI — Rani Therapeutics Holdings Inc

Rani Therapeutics Holdings Inc (RANI) is a biotechnology company listed on NASDAQ. It is led by Talat Imran, based in 2051 Ringwood Avenue, San Jose, CA, United States, 95131, with about 105 employees. Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; RT-116 which is in discovery stage for the treatment of obesity; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. The has a collaboration agreement with ProGen Co., Ltd. for the o-development and commercialization of RT-114 to treat obesity. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.

Latest reported RANI revenue for 2025-09-30 was $0. Net income was -$7.9M. RANI currently screens at market cap $41.5M.

Use this RANI page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the RANI quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the RANI SEC filings page. Lician reads the product cache first so this HTML stays unique to Rani Therapeutics Holdings Inc even when a live quote feed is slow.